

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <u>www.bccancer.bc.ca/terms-of-use</u> and according to acceptable standards of care.

PROTOCOL CODE: BRAVTR

Page 1 of 2

| DOCTOR'S ORDERS | Ht | cm | Wt | kg | BSA | m² | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|----|----|------------|-----------------|------|--|
| REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form | | | | | | | |
| DATE: To | DATE: To be given: Cyc | | | Cycle # of | f Trastuzum | nab: | |
| Date of Previous Cycle: | | | | | | | |
| Indicate the number of trastuzumab doses patient has received together with chemotherapy (not as single-agent) to date: | | | | | | | |
| Have Hypersensitivity Reaction Tray and Protocol Available | | | | | | | |
| TREATMENT: Cycle 1 (NEW patients ONLY – Omit for patients continuing single-agent trastuzumab following a trastuzumab-containing chemotherapy regimen): trastuzumab-containing chemotherapy regimen): trastuzumab 8 mg / kg x kg =mg IV in 250 mL NS over 1 hour 30 minutes. Observe for 1 hour post infusion*. Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190 Drug Brand (Pharmacist to complete. Please print.) Pharmacist Initial and Date trastuzumab | | | | | | | |
| Cycle 3 and Subsequent: (For patients who have just completed a trastuzumab-containing chemotherapy regimen) trastuzumab 6 mg/kg xkg =mg IV in 250 mL NS over 30 minutes** every three weeks x cycle(s). Observe for 30 minutes post-infusion*. Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190 Drug Brand (Pharmacist to complete. Please print.) Pharmacist Initial and Date trastuzumab trastuzumab * Observation period not required after 3 treatments with no reaction *** 30 minute infusion time for Cycle 3 and all subsequent cycles, if no previous adverse reactions. acetaminophen 325 to 650 mg PO PRN for headache and rigors Proceed with treatment based on blood work from | | | | | | | |
| DOCTOR'S SIGNATURE: | | | | | SIGNATUI UC: | RE: | |



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <u>www.bccancer.bc.ca/terms-of-use</u> and according to acceptable standards of care.

PROTOCOL CODE: BRAVTR

Page 2 of 2

| DOCTOR'S ORDERS Htcm | Wt | kg | BSAm ² | | |
|---------------------------------------------------|---------|----|-------------------|--|--|
| DATE: | | | | | |
| RETURN APPOINTMENT ORDERS | | | | | |
| Return in three weeks for Doctor and Cycle | | | | | |
| Return in weeks for Doctor and Cycle(s) | | | | | |
| CBC & Diff, platelets prior to Cycle #2 | | | | | |
| CBC & Diff, platelets every 12 weeks | | | | | |
| If clinically indicated xweeks: | | | | | |
| ECG Echocardiogram MUGA Scan C | A15-3 | | | | |
| □ Tot. Prot □ Albumin □ Bilirubin □ GGT □ Al | k Phos. | | | | |
| LDH ALT BUN Creatinine | | | | | |
| Other tests: | | | | | |
| Consults: | | | | | |
| See general orders sheet for additional requests. | | | | | |
| DOCTOR'S SIGNATURE: | | | SIGNATURE: | | |
| | | | UC: | | |